Switch theme
Sign up to access all valuation multiples
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
2009
20
LTM Revenue $0.2M
Last FY EBITDA -$9.5M
$71.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Entera Bio has a last 12-month revenue (LTM) of $0.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Entera Bio achieved revenue of $0.2M and an EBITDA of -$9.5M.
Entera Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Entera Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | $0.2M | XXX | $9K | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 5% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$9.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -5270% | XXX | XXX | XXX |
| EBIT | -$18.0M | XXX | -$9.6M | XXX | XXX | XXX |
| EBIT Margin | -9924% | XXX | -5296% | XXX | XXX | XXX |
| Net Profit | -$17.3M | XXX | -$9.5M | XXX | XXX | XXX |
| Net Margin | -9582% | XXX | -5271% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Entera Bio's stock price is $2.
Entera Bio has current market cap of $83.9M, and EV of $71.5M.
See Entera Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $71.5M | $83.9M | XXX | XXX | XXX | XXX | $-0.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Entera Bio has market cap of $83.9M and EV of $71.5M.
Entera Bio's trades at 395.1x EV/Revenue multiple, and -7.5x EV/EBITDA.
Equity research analysts estimate Entera Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Entera Bio has a P/E ratio of -4.8x.
See valuation multiples for Entera Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $83.9M | XXX | $83.9M | XXX | XXX | XXX |
| EV (current) | $71.5M | XXX | $71.5M | XXX | XXX | XXX |
| EV/Revenue | 395.1x | XXX | 395.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.5x | XXX | XXX | XXX |
| EV/EBIT | -4.0x | XXX | -7.5x | XXX | XXX | XXX |
| EV/Gross Profit | 395.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.8x | XXX | -8.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEntera Bio's revenue per employee in the last FY averaged $9K, while opex per employee averaged $0.5M for the same period.
Entera Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Entera Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Entera Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -5270% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $9K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2486% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 5301% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Entera Bio acquired XXX companies to date.
Last acquisition by Entera Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Entera Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Entera Bio founded? | Entera Bio was founded in 2009. |
| Where is Entera Bio headquartered? | Entera Bio is headquartered in United States of America. |
| How many employees does Entera Bio have? | As of today, Entera Bio has 20 employees. |
| Who is the CEO of Entera Bio? | Entera Bio's CEO is Ms. Miranda Jayne Toledano. |
| Is Entera Bio publicy listed? | Yes, Entera Bio is a public company listed on NAS. |
| What is the stock symbol of Entera Bio? | Entera Bio trades under ENTX ticker. |
| When did Entera Bio go public? | Entera Bio went public in 2018. |
| Who are competitors of Entera Bio? | Similar companies to Entera Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Entera Bio? | Entera Bio's current market cap is $83.9M |
| What is the current revenue of Entera Bio? | Entera Bio's last 12 months revenue is $0.2M. |
| What is the current EV/Revenue multiple of Entera Bio? | Current revenue multiple of Entera Bio is 395.1x. |
| Is Entera Bio profitable? | Yes, Entera Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
